PVLA
Palvella Therapeutics, Inc.96.81
+7.83+8.8%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
1.15BP/E (TTM)
-Basic EPS (TTM)
-2.92Dividend Yield
0%Recent Filings
8-K
Palvella launches $200M stock offering
Palvella Therapeutics inked an underwriting deal on February 25, 2026, to sell 1,600,000 common shares at $125.00 each, targeting ~$187.3 million in net proceeds. Funds will fuel QTORIN rapamycin and pitavastatin development, plus working capital. Underwriters hold a 30-day option for 240,000 more shares. Closing eyed for February 27.
8-K
Preliminary $55.9M cash
8-K
Phase 3 success in LMs
Palvella Therapeutics announced positive Phase 3 SELVA topline results on February 24, 2026, with QTORIN rapamycin gel hitting its primary endpoint (+2.13 mean mLM-IGA improvement, p<0.0001) and key secondary (p<0.0001) in microcystic lymphatic malformations. Well-tolerated, with 95% of completers improved and 98% continuing in extension. NDA planned for H2 2026. Data de-risks approval path.
8-K
Positive Phase 3 SELVA topline
Palvella Therapeutics announced positive Phase 3 SELVA topline results for QTORIN 3.9% rapamycin gel in microcystic lymphatic malformations on February 24, 2026. The trial hit its primary endpoint with a mean mLM-IGA improvement of +2.13 (p<0.0001) at week 24 in 49 ITT patients, plus key secondary endpoints. Well-tolerated, with 70% any AEs but no severe drug-related issues. NDA planned for 2H 2026.
8-K
Presentation posted; catalysts ahead
Palvella Therapeutics posted its January 2026 corporate presentation on its website for investor meetings. It highlights QTORIN rapamycin's Phase 3 mLM topline data due March 2026, positive Phase 2 cVM results from December 2025, and pipeline expansions including angiokeratomas and DSAP programs. Cash funds operations into 2H 2027. Catalysts loom large.
ARQT
Arcutis Biotherapeutics, Inc.
28.53-0.42
BLRX
BioLineRx Ltd.
3.01-0.17
KALA
KALA BIO, Inc.
0.56-0.05
LIPO
Lipella Pharmaceuticals Inc.
0.30-0.01
LRMR
Larimar Therapeutics, Inc.
3.74-0.18
MURA
Mural Oncology plc
2.04+2.04
PMVP
PMV Pharmaceuticals, Inc.
1.18-0.02
PTNT
Palatin Technologies, Inc.
22.82+8.33
RCKT
Rocket Pharmaceuticals, Inc.
3.43+0.02
TELA
TELA Bio, Inc.
1.18+0.05